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The treatment of advanced pleural malignancies, such asmalignant pleural mesothelioma (MPM), remains gener-
ally ineffective despite the use of surgery, external beam
radiation therapy, and chemotherapy individually or in com-
bination.1,2 Given the current lack of effective therapies, new
treatment approaches for MPM are clearly needed, including
the novel approach of intrapleural genetic immunotherapy.
MPM is a particularly attractive target for gene transfer
studies because of the paucity of effective therapies and the
relative accessibility of the tumors in the pleural space for
delivery of experimental therapies. Because MPM rarely
metastasizes early to distant sites, treatment of the primary
tumor can lead to significant palliative benefits and may
potentially prolong survival.
Cancer gene therapy is defined as the transfer of genetic
material, including full-length genes, complementary DNA,
RNA, or oligonucleotides, into cancer or host cells for the
ultimate purpose of killing an autologous tumor. The basis for
cytokine gene therapy in MPM lies not only in the direct
antiproliferative effects on mesothelioma cells but also in the
ability of certain cytokines to activate systemic, intrapleural,
and intratumoral immune effector cells. Although mesotheli-
oma is well known to inhibit host cellular and humoral
anti-tumor immune responses, animal and clinical data sup-
port the use of immunotherapeutic approaches.3,4 Prolonged
local cytokine expression can activate tumor-associated den-
dritic cells to phagacytose tumor antigens (after the induction
of tumor cell apoptosis) and to express these antigens on
major histocompatibility complex heterodimers in conjunc-
tion with costimulatory molecules. These activated dendritic
cells can then migrate to regional lymph nodes, where they
stimulate the proliferation of CD4 and CD8 lymphocytes, in-
ducing anti-tumoral cytotoxicity at distant tumor sites. Several
published phase I and phase II clinical trials have documented
mesothelioma tumor responses to intrapleural infusion of inter-
leukin-2 (IL-2), interferon (IFN)-, and IFN-.5–10
INTERFERONS
IFNs (especially type I IFNs like IFN- and -) are
known to inhibit tumor cell growth and stimulate the immune
system.11 IFNs have immunoregulatory effects on antibody
production, natural killer (NK) and T-cell activation, macro-
phage function, delayed-type hypersensitivity, and major his-
tocompatibility complex antigen expression, as well as anti-
proliferative effects and anti-angiogenic properties.12–16 The
results of human clinical trials of IFNs in the treatment of
various solid tumors have yielded disappointing results. This
is, in part, related to the short plasma half-life of IFNs after
systemic, local, or subcutaneous injection with a resulting
lack of sustained tissue levels.17 Doses of systemic IFNs
necessary to achieve intratumoral levels equivalent to those
found in vitro to induce cytostatic and anti-proliferative
effects are associated with significant, and likely intolerable,
toxicity.18 The rationale behind the use of gene transfer
approaches to cytokine therapy is that local, continuous
delivery and production of IFNs in and around tumors would
compensate for the short half-life of IFNs, inhibit tumor
growth and metastasis, and minimize systemic side effects.
IFN- gene transfer in animal models of various ma-
lignancies (both xenografts and autologous tumors) has dem-
onstrated impressive anti-tumor effects (Figure 1).19–22 Pre-
clinical studies in MPM have demonstrated that: 1) an
adenoviral vector encoding mouse IFN- (Ad.IFN-) had
dramatic therapeutic efficacy in syngeneic animal models of
MPM;23–25 2) intraperitoneal and intratumoral injections of
Ad.IFN- showed significant activity both in the injected
tumor and in distant tumors;23–25 and 3) in these models, this
effect was immunologic, in large part because of the gener-
ation of cytotoxic T-lymphocytes directed against as yet
undetermined tumor antigens and activation of natural killer
cells. These experiments served as the basis for the initiation
of a phase I clinical trial.
We hypothesized that the intracavitary administration
of Ad.IFN- through an indwelling pleural catheter would be
an effective local and systemic treatment for advanced tho-
racic malignancies, such as MPM. After confirming vector
safety in extensive rodent experiments, we initiated a single-
center dose-escalation phase I clinical trial assessing the
safety of single-dose intrapleural infusion of Ad.IFN- in
patients with MPM (and patients with metastatic pleural
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effusions).26 Secondary goals of the phase I clinical trial
included evaluation of induced anti-vector and anti-tumor
immune responses, viral shedding, and any discernible clin-
ical responses. Given the ability to sample the pleural space
with the indwelling catheter, we could also monitor intrapleu-
ral gene expression and immunologic responses. The results
of this trial demonstrated that intrapleural Ad.INF- was well
tolerated, generated anti-tumor immune response in almost
all of the patients, and resulted in encouraging anti-tumor
activity (unpublished data).26
FUTURE DIRECTIONS
Although we may be able to generate anti-tumor re-
sponses with intrapleural Ad.IFN-, we believe that, in bulky
tumors, this will not likely be sufficient to effect a significant
clinical response because of a low effector cell to target cell
(tumor) ratio, strong immunosuppressive effects (mediated
by factors such as prostaglandin E2, transforming growth
factor , or interleukin-10) within the tumor microenvironment,
and restrictions of leukocyte trafficking. It is our hypothesis that
the generation of anti-tumor reactive T-cells by administration of
Ad.IFN- will not be optimally effective unless other ap-
proaches are used to block immunologic checkpoints and en-
hance trafficking into tumors. Studies performed by our group
have shown the utility of multiple vector dose administration,
tumor debulking,27 adjuvant COX-2 inhibitors,28 and immuno-
modulatory chemotherapy (with drugs such as gemcitabine)
when combined with Ad.IFN- gene transfer. A second phase I
study of repeated-dose intrapleural Ad.INF- is currently ongo-
ing at our institution, and the combination of Ad.IFN- with
surgery, chemotherapy, and/or COX-2 inhibitors will be incor-
porated into future phase II trials.
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